Lexicon Pharmaceuticals (LXRX) Change in Cash (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Change in Cash for 17 consecutive years, with $3.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash rose 199.87% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $4.2 million (up 112.5% YoY), while the FY2025 annual figure was -$3.3 million, down 107.54% from the prior year.
• Change in Cash advanced to $3.8 million in Q1 2026 per LXRX's latest filing, from -$15.3 million in the prior quarter.
• Across five years, Change in Cash topped out at $76.3 million in Q2 2023 and bottomed at -$81.2 million in Q3 2023.
• Historically, Change in Cash has averaged $177882.4 across 5 years, with a median of -$2.6 million in 2022.
• Annual changes were most pronounced in 2023 — Change in Cash sank 3002.26% — and 2025, when it surged 2754.03%.
• Lexicon Pharmaceuticals' Change in Cash stood at $27.5 million in 2022, then slumped by 95.1% to $1.3 million in 2023, then jumped by 2279.91% to $32.1 million in 2024, then slumped by 147.75% to -$15.3 million in 2025, then soared by 124.55% to $3.8 million in 2026.
• Business Quant data shows LXRX's Change in Cash at $3.8 million in Q1 2026, -$15.3 million in Q4 2025, and $28.3 million in Q3 2025.